By Bruce Buckely
As the introduction of costly new targeted cancer therapies continues to increase, health care payors are turning more to real-world evidence (RWE) to help resolve formulary and patient coverage dilemmas, according to speakers at this week’s AMCP NEXUS 2020 Virtual meeting.